<DOC>
	<DOCNO>NCT00791167</DOCNO>
	<brief_summary>The purpose study evaluate dose proportionality 1.5- 3 mg tablet paliperidone ER , document pharmacokinetics 1.5 mg dose paliperidone ER , assess safety tolerability 1.5- 3 mg tablet healthy men .</brief_summary>
	<brief_title>A Study Dose Proportionality Extended Release Paliperidone</brief_title>
	<detailed_description>This randomize , open label , single center , single dose , 2 treatment , 2 way crossover study . It consist 3 phase : A screening phase begin within 21 day first study drug administration ; open label treatment phase consist 2 treatment period ( Period 1 Period 2 ) volunteer receive single oral 1.5 3 mg dose study drug ; end study evaluation upon completion study procedure Period 2 . All volunteer receive follow 2 treatment random order : Treatment A : One tablet 1.5 mg paliperidone ER to-be-marketed formulation fast state ; Treatment B : One tablet 3 mg paliperidone ER Phase 3 formulation fast state . Successive study drug administration separate washout period least 9 day 21 day . A 1.5-mg dose paliperidone ER select studied availability 1.5-mg tablet would make dose-adjustments across exist range dose paliperidone ER easy patient reduce renal function tolerability issue . Safety tolerability 1.5- 3 mg tablet paliperidone ER healthy men monitor throughout study . A single oral dos 1.5 mg 3 mg paliperidone ER</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Body mass index ( weight [ kg ] /height [ m2 ] ) 18 30 kg/m2 , inclusive Have supine ( 5 minute rest ) blood pressure 100 140 mmHg systolic , inclusive , 50 90 mmHg diastolic , inclusive Healthy basis prestudy physical examination , medical history , 12lead ECG , laboratory result serum chemistry , hematology , urinalysis perform within 21 day first dose . If result serum chemistry , hematology , urinalysis test within laboratory 's reference range , volunteer include investigator judge deviation clinically significant . For renal function test , value must within normal laboratory reference range Known drug allergy risperidone , paliperidone , excipients Known history druginduced dystonia Recent history alcohol substance abuse Relevant history presence cardiovascular ( include myocardial infarct cardiac arrhythmia ) , respiratory , neurologic ( include seizure ) , psychiatric , renal , hepatic , gastrointestinal ( include surgery , severe gastrointestinal narrowing , malabsorption problem ) , endocrine , hematologic , immunologic disease History cancer , exception basal cell carcinoma At screening , sign autonomic dysfunction indicate sustained decrease &gt; 20 mmHg systolic blood pressure decrease &gt; 10 mmHg diastolic blood pressure stand least 2 minute associated increase &gt; 15 beat per minute ( bpm ) heart rate Bradycardia ( heart rate &lt; 50 bpm ) determine screen 12lead ECG A positive test result ( history ) serology test ( hepatitis B C , human immunodeficiency virus ) screen History smoking use nicotinecontaining substance within last 2 month , determine medical history and/or volunteer 's verbal report . Volunteers must agree refrain use throughout study Use prescription nonprescription medication ( include vitamin herbal supplement ) within 14 day first dose study drug . Exception acetaminophen ( paracetamol ) ibuprofen , allow 3 day first dose study drug</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Mood Disorders , Antipsychotic drug</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Paliperidone ER</keyword>
</DOC>